A&M Adds Healthcare, Due Diligence Specialists

Jan 23 2013 | 1:06pm ET

Professional services firm Alvarez & Marsal has made two senior hires.

Financial industry vet Osman Khan has joined A&M's transaction advisory group as a managing director while healthcare executive Steve Geringer joins as a managing director to lead A&M Healthcare's private equity services. Both men will be based in New York.

Formerly with PricewaterhouseCoopers’ transaction services practice, Khan brings more than 15 years of experience providing mergers and acquisitions due diligence and other advisory services to financial services clients. In his new role at A&M, Khan will focus on pre- and post-acquisition due diligence and divestiture services for strategic and financial investors, across the broader financial services sector.

Geringer brings significant experience working with organizations focused on hospital management, outpatient services, managed care, pharmaceutical benefits, behavioral health and social services, and healthcare information technology. Prior to joining A&M, he held senior posts with Infuscience (acquired by Bioscript); CredenceHealt (acquired by Midas+ Solutions) and CCRx Pharmaceutical Services (acquired by Omnicare). He also serves as chairman of Amsurg Corp, is a director of Addus Homecare, chairman of Qualifacts Systems and a director of Woundcare Specialists.


In Depth

Steinbrugge: Top 10 Hedge Fund Industry Trends for 2017

Jan 3 2017 | 9:03pm ET

Each year, Agecroft Partners' Don Steinbrugge predicts the top hedge fund industry...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

DarcMatter: The Top Trends in Alternative Investments for 2017

Jan 13 2017 | 8:22pm ET

The $7 trillion alternative investments industry is poised for continued growth...

 

From the current issue of

The U.S. Commodity Futures Trading Commission (CFTC) ordered The Goldman Sachs Group Inc., and Goldman, Sachs & Co. to pay a $120 million penalty for attempted manipulation and false reporting of ISDAFIX Benchmark Rates, a global benchmark for interest rate products.